m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04176)
Name
BI-505
Status
Phase 2
TTD Drug ID
D0Q7OE
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Intercellular adhesion molecule ICAM-1 (ICAM1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for BI-505. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of BI-505 through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for BI-505. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BI-505 through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). [2], [3]
Tyrosine-protein kinase UFO (AXL)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tyrosine-protein kinase UFO (AXL) is a therapeutic target for BI-505. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BI-505 through regulating the expression of Tyrosine-protein kinase UFO (AXL). [4], [5]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tyrosine-protein kinase UFO (AXL) is a therapeutic target for BI-505. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BI-505 through regulating the expression of Tyrosine-protein kinase UFO (AXL). [5], [6]
References
Ref 1 N6-Methyladenosine Demethylase FTO (Fat Mass and Obesity-Associated Protein) as a Novel Mediator of Statin Effects in Human Endothelial Cells. Arterioscler Thromb Vasc Biol. 2022 May;42(5):644-658. doi: 10.1161/ATVBAHA.121.317295. Epub 2022 Mar 17.
Ref 2 Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett. 2012 Jan 31;3(3):203-6. doi: 10.1021/ml2002482. eCollection 2012 Mar 8.
Ref 3 N(6)-Methyladenosine METTL3 Modulates the Proliferation and Apoptosis of Lens Epithelial Cells in Diabetic Cataract. Mol Ther Nucleic Acids. 2020 Jun 5;20:111-116. doi: 10.1016/j.omtn.2020.02.002. Epub 2020 Feb 11.
Ref 4 METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition. Gynecol Oncol. 2018 Nov;151(2):356-365. doi: 10.1016/j.ygyno.2018.09.015. Epub 2018 Sep 21.
Ref 5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 6 Leukemogenic Chromatin Alterations Promote AML Leukemia Stem Cells via a KDM4C-ALKBH5-AXL Signaling Axis. Cell Stem Cell. 2020 Jul 2;27(1):81-97.e8. doi: 10.1016/j.stem.2020.04.001. Epub 2020 May 12.